HRP20181079T1 - Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja - Google Patents

Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja Download PDF

Info

Publication number
HRP20181079T1
HRP20181079T1 HRP20181079TT HRP20181079T HRP20181079T1 HR P20181079 T1 HRP20181079 T1 HR P20181079T1 HR P20181079T T HRP20181079T T HR P20181079TT HR P20181079 T HRP20181079 T HR P20181079T HR P20181079 T1 HRP20181079 T1 HR P20181079T1
Authority
HR
Croatia
Prior art keywords
sirna
use according
eye
administered
treatment
Prior art date
Application number
HRP20181079TT
Other languages
English (en)
Croatian (hr)
Inventor
Ana Isabel Jimenez Anton
Victoria GONZALEZ FAJARDO
Veronica RUZ PALOMAR
Original Assignee
Sylentis S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis S.A.U. filed Critical Sylentis S.A.U.
Publication of HRP20181079T1 publication Critical patent/HRP20181079T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HRP20181079TT 2012-09-05 2013-09-04 Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja HRP20181079T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1215857.2A GB201215857D0 (en) 2012-09-05 2012-09-05 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
EP13759707.6A EP2893019B1 (en) 2012-09-05 2013-09-04 Sirna and its use in methods and compositions for the treatment and/or prevention of eye conditions
PCT/EP2013/068245 WO2014037377A1 (en) 2012-09-05 2013-09-04 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
HRP20181079T1 true HRP20181079T1 (hr) 2018-09-07

Family

ID=47136985

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20181079TT HRP20181079T1 (hr) 2012-09-05 2013-09-04 Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja

Country Status (29)

Country Link
US (1) US9808479B2 (OSRAM)
EP (1) EP2893019B1 (OSRAM)
JP (2) JP2015529210A (OSRAM)
KR (1) KR102136539B1 (OSRAM)
CN (2) CN104640988A (OSRAM)
AU (1) AU2013311781B2 (OSRAM)
BR (1) BR112015004469B8 (OSRAM)
CA (1) CA2883040C (OSRAM)
CL (1) CL2015000537A1 (OSRAM)
CY (1) CY1121000T1 (OSRAM)
DK (1) DK2893019T3 (OSRAM)
EC (1) ECSP15009391A (OSRAM)
ES (1) ES2685346T3 (OSRAM)
GB (1) GB201215857D0 (OSRAM)
HR (1) HRP20181079T1 (OSRAM)
HU (1) HUE040096T2 (OSRAM)
IL (1) IL237389B (OSRAM)
IN (1) IN2015DN02501A (OSRAM)
LT (1) LT2893019T (OSRAM)
MX (1) MX362854B (OSRAM)
PE (1) PE20150619A1 (OSRAM)
PL (1) PL2893019T3 (OSRAM)
PT (1) PT2893019T (OSRAM)
RS (1) RS57620B1 (OSRAM)
RU (1) RU2663100C2 (OSRAM)
SG (1) SG11201501386TA (OSRAM)
SI (1) SI2893019T1 (OSRAM)
WO (1) WO2014037377A1 (OSRAM)
ZA (1) ZA201501494B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102434346B1 (ko) 2011-06-30 2022-08-18 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
EP3332007A4 (en) 2015-08-07 2019-07-17 Arrowhead Pharmaceuticals, Inc. RNAi Therapy Against Infection with Hepatitis B Virus
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
JOP20210217A1 (ar) 2019-02-15 2023-01-30 Novartis Ag طرق لعلاج ألم سطح عين
KR20220078604A (ko) * 2019-10-04 2022-06-10 센주 세이야꾸 가부시키가이샤 헤테로시클리덴아세트아미드 유도체 함유 의약

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
US20040259247A1 (en) 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003059267A2 (en) 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
ES2397060T3 (es) 2002-04-18 2013-03-04 Opko Pharmaceuticals, Llc Medios y métodos para la modulación específica de genes diana en el ojo
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
WO2004009794A2 (en) 2002-07-24 2004-01-29 Immusol, Inc. NOVEL siRNA LIBRARIES AND THEIR PRODUCTION AND USE
JP2005533504A (ja) 2002-07-24 2005-11-10 イミューソル インコーポレイテッド ポリメラーゼプライマーヘアピンリンカーを用いたｓｉＲＮＡ発現カセット及び発現ライブラリーの製造用単一プロモーター系
PT1527176E (pt) 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
WO2004029212A2 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
CA2504926C (en) 2002-11-01 2014-01-14 The Trustees Of The University Of Pennsylvania Compositions and methods for sirna inhibition of hif-1 alpha
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
US7462602B2 (en) 2003-05-01 2008-12-09 University Of Florida Research Foundation, Inc. Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
EP1636342A4 (en) 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMER COMPOUNDS FOR USE IN THE MODULATION OF GENES
US7338950B2 (en) 2003-10-07 2008-03-04 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20050039573A (ko) 2003-10-23 2005-04-29 주식회사 태평양 티오우레아계 유도체의 용해성과 생체이용률이 개선된약제학적 조성물
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
DK1699924T3 (da) * 2003-12-03 2019-10-21 Ocunexus Therapeutics Inc Connexin 43-målrettede hæmmende forbindelser og fremgangsmåder til anvendelse deraf i behandling af hornhindetraume
US7544803B2 (en) 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
EP2365077B1 (en) 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
JP2008504280A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CN102895673A (zh) 2004-08-23 2013-01-30 西伦蒂斯私人股份公司 眼病的治疗
TW200639253A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
MX2007010608A (es) 2005-03-11 2007-10-19 Alcon Inc Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma.
GB0521351D0 (en) 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
BRPI0715821A2 (pt) * 2006-08-24 2013-07-23 Alcon Res Ltd inibiÇço de gremlina mediada por rnai para tratamento de condiÇÕes relacionadas À iop
US20110160279A1 (en) 2007-08-13 2011-06-30 Board Of Trustees Of Southern Illinois University METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA
TW200927192A (en) 2007-11-19 2009-07-01 Alcon Res Ltd Use of TRPV1 receptor antagonists for treating dry eye and ocular pain
CN201337650Y (zh) * 2009-01-06 2009-11-04 河北科技大学 一次性药用单剂量液体容器
EP2390327A1 (en) * 2010-05-27 2011-11-30 Sylentis S.A. siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Also Published As

Publication number Publication date
AU2013311781B2 (en) 2018-10-18
EP2893019A1 (en) 2015-07-15
CA2883040C (en) 2023-01-17
CN108354944A (zh) 2018-08-03
SG11201501386TA (en) 2015-03-30
RU2663100C2 (ru) 2018-08-01
PE20150619A1 (es) 2015-05-11
ECSP15009391A (es) 2015-12-31
MX362854B (es) 2019-02-20
CN104640988A (zh) 2015-05-20
MX2015002802A (es) 2015-05-15
GB201215857D0 (en) 2012-10-24
SI2893019T1 (sl) 2018-09-28
IL237389B (en) 2019-01-31
US9808479B2 (en) 2017-11-07
IN2015DN02501A (OSRAM) 2015-09-11
AU2013311781A1 (en) 2015-03-12
BR112015004469B8 (pt) 2022-12-06
LT2893019T (lt) 2018-08-10
PL2893019T3 (pl) 2018-12-31
BR112015004469B1 (pt) 2022-11-16
RU2015112121A (ru) 2016-10-27
WO2014037377A1 (en) 2014-03-13
JP2018138596A (ja) 2018-09-06
HK1212377A1 (en) 2016-06-10
JP2015529210A (ja) 2015-10-05
CA2883040A1 (en) 2014-03-13
EP2893019B1 (en) 2018-05-30
ZA201501494B (en) 2016-01-27
US20150224131A1 (en) 2015-08-13
CY1121000T1 (el) 2019-12-11
IL237389A0 (en) 2015-04-30
HUE040096T2 (hu) 2019-02-28
CL2015000537A1 (es) 2015-07-10
RS57620B1 (sr) 2018-11-30
BR112015004469A2 (pt) 2017-08-08
KR102136539B1 (ko) 2020-07-23
DK2893019T3 (en) 2018-09-03
PT2893019T (pt) 2018-10-19
KR20150047513A (ko) 2015-05-04
ES2685346T3 (es) 2018-10-08
JP6742362B2 (ja) 2020-08-19

Similar Documents

Publication Publication Date Title
HRP20181079T1 (hr) Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
NZ606383A (en) Methods of treating pulmonary disorders with liposomal amikacin formulations
WO2011053792A3 (en) Methods and compositions for sustained delivery of drugs
JP2008044951A5 (OSRAM)
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
BR112013027670A2 (pt) "composto de amida, composição farmacêutica e medicamento que o compreende e antagonista de rory"
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
IL291556B2 (en) Methods and compositions for administration of arylsulfatase A to the central nervous system
HRP20251264T1 (hr) Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
PE20081578A1 (es) Formulacion en polvo de valganciclovir
JP2011503044A5 (OSRAM)
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
RU2015109296A (ru) Системы доставки лекарственного средства и способы лечения рака мочевого пузыря, включающие применение оксалиплатина
JP2018138596A5 (OSRAM)
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
RU2019118647A (ru) Композиции с кариофилленом, устройства для их введения и способы их использования
BR112013006632A2 (pt) composições e sistema de liberação de distribuição de droga aprimorados
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
RU2015145451A (ru) Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол